作者
Sylvan C Baca, Ji-Heui Seo, Matthew P Davidsohn, Brad Fortunato, Karl Semaan, Shahabbedin Sotudian, Gitanjali Lakshminarayanan, Miklos Diossy, Xintao Qiu, Talal El Zarif, Hunter Savignano, John Canniff, Ikenna Madueke, Renee Maria Saliby, Ziwei Zhang, Rong Li, Yijia Jiang, Len Taing, Mark Awad, Cindy H Chau, James A DeCaprio, William D Figg, Tim F Greten, Aaron N Hata, F Stephen Hodi, Melissa E Hughes, Keith L Ligon, Nancy Lin, Kimmie Ng, Matthew G Oser, Catherine Meador, Heather A Parsons, Mark M Pomerantz, Arun Rajan, Jerome Ritz, Manisha Thakuria, Sara M Tolaney, Patrick Y Wen, Henry Long, Jacob E Berchuck, Zoltan Szallasi, Toni K Choueiri, Matthew L Freedman
发表日期
2023/11
期刊
Nature medicine
卷号
29
期号
11
页码范围
2737-2741
出版商
Nature Publishing Group US
简介
Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the transcriptional programs that govern cancer phenotypes and their dynamic changes during the course of disease. To address these limitations, we developed a method for comprehensive epigenomic profiling of cancer from 1 ml of patient plasma. Using an immunoprecipitation-based approach targeting histone modifications and DNA methylation, we measured 1,268 epigenomic profiles in plasma from 433 individuals with one of 15 cancers. Our assay provided a robust proxy for transcriptional activity, allowing us to infer the expression levels of diagnostic markers and drug targets, measure the activity of therapeutically targetable transcription factors and detect epigenetic mechanisms of resistance. This proof-of-concept study in advanced cancers shows how …
学术搜索中的文章
SC Baca, JH Seo, MP Davidsohn, B Fortunato… - Nature medicine, 2023